Skip to Content

Synvexia TC Cream

Generic Name: lidocaine hydrochloride and menthol
Dosage Form: cream

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Rx Only

Synvexia TC 

Synvexia TC is a Lidocaine 4% and Menthol 1% Cream is a topical anesthetic indicated for the relief of pruritus, pruritic eczemas, abrasions, minor burns, insect bites, pain, soreness, and discomfort due to pruritus ani, pruritus vulvae, hemorrhoids, anal fissures, and similar conditions of the skin and mucous membranes.

Avtive Ingredients

Each gram of Synvexia TC Cream contains Lidocaine hydrochloride 4% (40 mg) and Menthol 1% (10mg).

Inactive Ingredients

Water, TEA Salicylate, Glycerin, Dimethyl Isosorbide, Glyceryl Stearate, PEG-100 Stearat, PEG-8, Vanillyl Butyl Ether, Cetyl Alcohol, Glyceryl Stearate, Tridecyl Stearate, Neopentyl Glycol Dicaprylate/Dicaprate, Tridecyl Trimellitate, Stearic Acid, Beeswax, Phenoxyethanol, Ethylhexylglycerin, Aloe Vera Gel, Acrylates/C10-30 Alkyl Acrylate Crosspolymer, Naproxen, Glucosamine, Sodium Hydroxide, Boswelia Extract, Arnica Oil, MSM, Citric Acid, Lemongrass Oil.

Clinical Pharmacology

Mechanism of Action

Synvexia TC Cream releases lidocaine from a mild acidic vehicle to stabilize the neuronal membrane by inhibiting the ionic fluxes required for initiation and conduction of impulses, thereby effecting local anesthetic action. A mild acidic vehicle lowers pH to increase protection against alkaline irritations and to provide a favorable environment for healing.
Lidocaine is chemically designated as acetamide, 2- (diethylamino)-N-(2,6- dimethylphenyl), and has the
following structure.

PHARMACOKINETICS

Lidocaine may be absorbed following topical administration to mucous membranes, its rate and extent of absorption depending upon the specific site of application, duration of exposure, concentration and total dosage. In general, the rate of absorption of local anesthetic agents following topical application occurs most rapidly after intratracheal administration. Lidocaine is also well- absorbed from the gastrointestinal tract, but little intact drug appears in the circulation because of biotransformation in the liver.
Lidocaine is metabolized rapidly by the liver and metabolites and unchanged drug are excreted by the kidneys. Biotransformation includes oxidative N-dealkylation, ring
hydroxylation, cleavage of the amide linkage and conjugation. N-dealkylation, a major pathway of biotransformation, yields the metabolites monoethylglycinexylidide and glycinexylidide. The pharmacological / toxicological actions of these metabolites are similar to, but less potent than, those of lidocaine. Approximately 90% of lidocaine administered is excreted in the form of various metabolites and less than 10% is excreted unchanged. The primary metabolite in urine is a conjugate of 4-hydroxy-2, 6- dimethylaniline. The plasma binding of lidocaine is dependent on drug concentration, and the fraction bound decreases with increasing concentration. At concentrations of 1to4goffreebasepermL,60to80percent of lidocaine is protein bound. Binding is also dependent on the plasma concentration of the alpha-1-acid glycoprotein. Lidocaine crosses the blood-brain and placental barriers, presumably by passive diffusion. Studies of lidocaine metabolism following intravenous bolus injections have shown that the elimination half-life of this agent is typically 1.5 to 2 hours. Because of the rapid rate at which lidocaine is metabolized, any condition that affects liver function may alter lidocaine kinetics. The half-life may be prolonged twofold or more in patients with liver dysfunction. Renal dysfunction does not affect lidocaine kinetics, but may increase the accumulation of metabolites. Factors such as acidosis and the use of CNS stimulants and depressants affect the CNS levels of lidocaine required to produce overt systemic effects. Objective adverse anifestations become increasingly apparent with increasing venous plasma levels above 6 g free base per mL. In the rhesus monkey, arterial blood levels of 18-21 g/mL have been shown to be threshold for convulsive activity.

Indications

Anesthetic for relief of pruritus, pruritic eczemas, abrasions, minor burns, insect bites, pain, soreness and discomfort due to pruritus ani, pruritus vulvae, hemorrhoids, anal fissures, and similar conditions of the skin and mucous membranes.

Contraindications

Traumatized mucosa, secondary bacterial infection of the area of proposed application and known hypersensitivity to any of the components. Lidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type.

Warnings

For external use only. Not for ophthalmic use.

Precautions

If irritation or sensitivity occurs or infection appears, discontinue use and institute appropriate therapy. Synvexia TC Cream should be used with caution in ill, elderly, debilitated patients and children who may be more sensitive to the systemic effects of lidocaine.

CARCINOGENESIS & MUTAGENESIS

Studies of lidocaine in animals to evaluate the carcinogenic and mutagenic potential of the effect on fertility have not been conducted.

Use in Pregnancy

Teratogenic Effects; Pregnancy Category B.
Reproduction studies have been performed for lidocaine in rats at doses up to 6.6 times the human dose and have revealed no evidence of harm to the fetus caused by lidocaine. There are, however, no adequate and well-controlled studies in pregnant women. Animal reproduction studies are not always predictive of human response. General consideration should be given to this fact before administering lidocaine to women of childbearing potential, especially during early pregnancy when maximum organogenesis takes place.

Nursing Mothers

Lidocaine is excreted in human milk. The clinical significance of this observation is unknown. Caution should be exercised when lidocaine is administered to a nursing woman.

Pediatric Use

Dosage in pediatric patients should be reduced commensurate with age, body weight and physical condition.

Adverse Reactions

During or immediately after treatment, the skin at the site of treatment may develop erythema or edema or may be the locus of abnormal sensation.

CALL YOUR DOCTOR ABOUT SIDE EFFECTS.
Call your doctor about side effects . You may report side effects to the FDA at 1- 800-FDA-1088.

Dosage and Administration

Apply a thin film to the affected area two or three times daily or as directed by a physician.

How Supplied

Synvexia TC Cream is supplied as a white cream in:
60 gram tube, NDC 69336-201-01

KEEP OUT OF REACH OF CHILDREN

KEEP THIS AND ALL MEDICATIONS OUT OF REACH OF CHILDREN.
All prescriptions using this product shall be pursuant to state statutes as applicable. This is not an Orange Book product. This product may be administered only under a physician’s supervision. There are no implied or explicit claims on the therapeutic equivalence.
Store at 25oC (77oF); excursions permitted to 15o-30oC (59o-86o F). See USP Controlled Room Temperature. Protect from freezing.
Manufactured for:
Sterling-Knight Pharmaceuticals, LLC Ripley, MS 38663

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

SYNVEXIA TC 
lidocaine hydrochloride and menthol cream
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:69336-201
Route of Administration TOPICAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
LIDOCAINE HYDROCHLORIDE (LIDOCAINE) LIDOCAINE HYDROCHLORIDE ANHYDROUS 4 g  in 100 g
MENTHOL (MENTHOL) MENTHOL 1 g  in 100 g
Inactive Ingredients
Ingredient Name Strength
WATER  
GLYCERIN  
DIMETHYL ISOSORBIDE  
TROLAMINE SALICYLATE  
GLYCERYL MONOSTEARATE  
PEG-100 STEARATE  
PEG-8 STEARATE  
VANILLYL BUTYL ETHER  
CETYL ALCOHOL  
TRIDECYL STEARATE  
NEOPENTYL GLYCOL DICAPRYLATE/DICAPRATE  
TRIDECYL TRIMELLITATE  
STEARIC ACID  
WHITE WAX  
PHENOXYETHANOL  
ETHYLHEXYLGLYCERIN  
ALOE VERA WHOLE  
NAPROXEN  
GLUCOSAMINE  
SODIUM HYDROXIDE  
BOSWELLIA SERRATA WHOLE  
ARNICA MONTANA  
MONOSODIUM METHYLARSONATE  
EAST INDIAN LEMONGRASS OIL  
(C10-C30)ALKYL METHACRYLATE ESTER  
CITRIC ACID MONOHYDRATE  
Product Characteristics
Color white Score     
Shape Size
Flavor Imprint Code
Contains         
Packaging
# Item Code Package Description
1 NDC:69336-201-01 60 g in 1 PACKAGE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
unapproved drug other 12/01/2014
Labeler - Sterling Knight Pharmaceuticals, LLC (079556942)
Revised: 12/2014
 
Sterling Knight Pharmaceuticals, LLC

More about Synvexia TC (lidocaine / menthol topical)

Consumer resources

Professional resources

Related treatment guides

Hide